FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Risto Juvonen

Research Profile

Chemicals & Drugs

Anatomy

Living Beings

Concepts & Ideas

Physiology

Enzyme Induction

Phenomena

Co-author Network

Publications

TOP 3
Kristiina M Huttunen; Risto O Juvonen; Hannu Raunio; Niina Tani; Jarkko Rautio
Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome p450-activated prodrugs.
Laura E Martikainen; Silvie Neshybova; Minna Rahnasto-Rilla; Hannu Raunio; Maija Lahtela-Kakkonen; Risto O Juvonen
Interactions of inhibitor molecules with the human CYP2E1 enzyme active site.
Rohit S Mulik; Risto O Juvonen; Kakasaheb Mahadik; Jukka Mönkkönen; Anant Paradkar
ApoE3 mediated polymeric nanoparticles containing curcumin: apoptosis induced in vitro anticancer activity against neuroblastoma cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Risto Juvonen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kristiina M Huttunen; Risto O Juvonen; Hannu Raunio; Niina Tani; Jarkko Rautio
Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome p450-activated prodrugs.
Molecular pharmaceutics 2013;10(2):532-7.
2012: Laura E Martikainen; Silvie Neshybova; Minna Rahnasto-Rilla; Hannu Raunio; Maija Lahtela-Kakkonen; Risto O Juvonen
Interactions of inhibitor molecules with the human CYP2E1 enzyme active site.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2012;47(5):996-1005.
2012: Rohit S Mulik; Risto O Juvonen; Kakasaheb Mahadik; Jukka Mönkkönen; Anant Paradkar
ApoE3 mediated polymeric nanoparticles containing curcumin: apoptosis induced in vitro anticancer activity against neuroblastoma cells.
International journal of pharmaceutics 2012;437(1-2):29-41.
2012: A'edah Abu-Bakar; Dionne M Arthur; Risto O Juvonen; Jack C Ng; Minna Rahnasto; Hannu Raunio; Jouko Vepsäläinen; Anna S Wikman; Matti A Lang
Metabolism of bilirubin by human cytochrome P450 2A6.
Toxicology and applied pharmacology 2012;261(1):50-8.
2012: Niina Tani; Carsten Wittekindt; Jenna Koskiranta; Riina Ollakka; Minna Rahnasto-Rilla; Hannu Raunio; Anniina Ritvanen; Kaisa A Salminen; Risto O Juvonen
Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
European journal of medicinal chemistry 2012;47(1):270-7.
2011: Minna K Rahnasto; Hannu A Raunio; Kaisa A Salminen; Carsten Wittekindt; Risto O Juvonen; Jukka Leppänen; Antti Poso; Maija K Lahtela-Kakkonen
Identification of novel CYP2A6 inhibitors by virtual screening.
Bioorganic & medicinal chemistry 2011;19(23):7186-93.
2011: AO Rantala; Sylvi Silvennoinen-Kassinen; Olli Vainio; Risto O Juvonen; Taina Lajunen; Maija Leinonen; Mika Paldanius; A Peitso; Pekka Saikku
Interleukin-6-174 G/C promoter polymorphism is associated with persistence of Chlamydia pneumoniae antibodies in young men.
Scandinavian journal of immunology 2011;74(1):95-9.
2011: Kaisa A Salminen; Achim Meyer; Lenka Jerabkova; Laura E Korhonen; Minna Rahnasto; Risto O Juvonen; Peter Imming; Hannu Raunio
Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids.
Phytomedicine : international journal of phytotherapy and phytopharmacology 2011;18(6):533-8.
2011: Kaisa A Salminen; Jukka Leppänen; Jarkko I Venäläinen; Markku Pasanen; Seppo Auriola; Risto O Juvonen; Hannu Raunio
Simple, direct, and informative method for the assessment of CYP2C19 enzyme inactivation kinetics.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(3):412-8.
2011: AO Rantala; Taina Lajunen; Risto O Juvonen; Aini Bloigu; Mika Paldanius; Sylvi Silvennoinen-Kassinen; Ari Peitso; Olli Vainio; Maija Leinonen; Pekka Saikku
Low mannose-binding lectin levels and MBL2 gene polymorphisms associate with Chlamydia pneumoniae antibodies.
Innate immunity 2011;17(1):35-40.
2010: Rohit S Mulik; Jukka Mönkkönen; Risto O Juvonen; Kakasaheb Mahadik; Anant Paradkar
Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis.
International journal of pharmaceutics 2010;398(1-2):190-203.
2010: Ulla Jounio; Risto O Juvonen; Aini Bloigu; Sylvi Silvennoinen-Kassinen; Tarja Kaijalainen; Heikki Kauma; Ari Peitso; Annika Saukkoriipi; Olli Vainio; Terttu Harju; Maija Leinonen
Pneumococcal carriage is more common in asthmatic than in non-asthmatic young men.
The clinical respiratory journal 2010;4(4):222-9.
2010: Rohit S Mulik; Jukka Mönkkönen; Risto O Juvonen; Kakasaheb Mahadik; Anant Paradkar
ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model.
Molecular pharmaceutics 2010;7(3):815-25.
2010: Ulla Jounio; Aino Rantala; Aini Bloigu; Risto O Juvonen; Taina Lajunen; Sylvi Silvennoinen-Kassinen; Ari Peitso; Olli Vainio; Terttu Harju; Annika Saukkoriipi; Maija Leinonen
Smoking status interacts with the association between mannose-binding lectin serum levels and gene polymorphism and the carriage of oropharyngeal bacteria.
Human immunology 2010;71(3):298-303.
2009: Tiina M Mäkinen; Risto O Juvonen; Jari Jokelainen; Terttu Harju; Ari Peitso; Aini Bloigu; Sylvi Silvennoinen-Kassinen; Maija Leinonen; Juhani Hassi
Cold temperature and low humidity are associated with increased occurrence of respiratory tract infections.
Respiratory medicine 2009;103(3):456-62.
2009: J E Laine; Seppo Auriola; Markku Pasanen; Risto O Juvonen
Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes.
Xenobiotica; the fate of foreign compounds in biological systems 2009;39(1):11-21.
2008: Minna Rahnasto; Carsten Wittekindt; Risto O Juvonen; Miia Turpeinen; A Petsalo; Olavi Pelkonen; Antti Poso; Gunther Stahl; H-D Höltje; Hannu Raunio
Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach.
The pharmacogenomics journal 2008;8(5):328-38.
2008: Hannu Raunio; N Pokela; K Puhakainen; Minna Rahnasto; Timo Mauriala; Seppo Auriola; Risto O Juvonen
Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo.
Xenobiotica; the fate of foreign compounds in biological systems 2008;38(1):34-47.
2007: Mikko J Myllymäki; Susanna M Saario; Antti O Kataja; Joel A Castillo-Melendez; Tapio Nevalainen; Risto O Juvonen; Tomi Järvinen; ari koskinen
Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors.
Journal of medicinal chemistry 2007;50(17):4236-42.
2007: S Gratz; Q K Wu; Hani El-Nezami; Risto O Juvonen; Hannu M Mykkänen; Paul C Turner
Lactobacillus rhamnosus strain GG reduces aflatoxin B1 transport, metabolism, and toxicity in Caco-2 Cells.
Applied and environmental microbiology 2007;73(12):3958-64.
2007: Kristiina M Huttunen; Niina Mähönen; Jukka Leppänen; Jouko Vepsäläinen; Risto O Juvonen; Hannu Raunio; Hanna Kumpulainen; Tomi Järvinen; Jarkko Rautio
Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.
Pharmaceutical research 2007;24(4):679-87.
2007: Laura E Korhonen; Miia Turpeinen; Minna Rahnasto; Carsten Wittekindt; Antti Poso; Olavi Pelkonen; Hannu Raunio; Risto O Juvonen
New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis.
British journal of pharmacology 2007;150(7):932-42.
2006: S Gratz; M Täubel; Risto O Juvonen; M Viluksela; Paul C Turner; Hannu M Mykkänen; Hani El-Nezami
Lactobacillus rhamnosus strain GG modulates intestinal absorption, fecal excretion, and toxicity of aflatoxin B(1) in rats.
Applied and environmental microbiology 2006;72(11):7398-400.
2006: Miia Turpeinen; Laura E Korhonen; Ari Tolonen; Jouko Uusitalo; Risto O Juvonen; Hannu Raunio; Olavi Pelkonen
Cytochrome P450 (CYP) inhibition screening: comparison of three tests.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2006;29(2):130-8.
2006: Susanna M Saario; Antti Poso; Risto O Juvonen; Tomi Järvinen; Outi M H Salo-Ahen
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.
Journal of medicinal chemistry 2006;49(15):4650-6.
2006: Hani El-Nezami; Nektaria Polychronaki; Jing Ma; Huilian Zhu; Wenhua Ling; Eeva K Salminen; Risto O Juvonen; Seppo J Salminen; Tuija Poussa; Hannu M Mykkänen
Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China.
The American journal of clinical nutrition 2006;83(5):1199-203.
2006: Hanna Kumpulainen; Niina Mähönen; Marja-Leena Laitinen; Marja Jaurakkajärvi; Hannu Raunio; Risto O Juvonen; Jouko Vepsäläinen; Tomi Järvinen; Jarkko Rautio
Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.
Journal of medicinal chemistry 2006;49(3):1207-11.
2005: Hannu M Mykkänen; Huilian Zhu; Eeva Salminen; Risto O Juvonen; Wenhua Ling; Jing Ma; Nektaria Polychronaki; Heidi Kemiläinen; Otto Mykkänen; Seppo Salminen; Hani El-Nezami
Fecal and urinary excretion of aflatoxin B1 metabolites (AFQ1, AFM1 and AFB-N7-guanine) in young Chinese males.
International journal of cancer. Journal international du cancer 2005;115(6):879-84.
2005: Laura E Korhonen; Minna Rahnasto; Niina Mähönen; Carsten Wittekindt; Antti Poso; Risto O Juvonen; Hannu Raunio
Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.
Journal of medicinal chemistry 2005;48(11):3808-15.
2005: Minna Rahnasto; Hannu Raunio; Antti Poso; Carsten Wittekindt; Risto O Juvonen
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Journal of medicinal chemistry 2005;48(2):440-9.
2004: Hannu Raunio; Päivi Taavitsainen; Paavo Honkakoski; Risto O Juvonen; Olavi Pelkonen
In vitro methods in the prediction of kinetics of drugs: focus on drug metabolism.
Alternatives to laboratory animals : ATLA 2004;32(4):425-30.
2004: S Gratz; Hannu M Mykkänen; A C Ouwehand; Risto O Juvonen; Seppo Salminen; Hani El-Nezami
Intestinal mucus alters the ability of probiotic bacteria to bind aflatoxin B1 in vitro.
Applied and environmental microbiology 2004;70(10):6306-8.
2004: Markus M Forsberg; Risto O Juvonen; Petra Helisalmi; Jukka Leppänen; Joseph A Gogos; Maria Karayiorgou; Pekka T Männistö
Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice.
Naunyn-Schmiedeberg's archives of pharmacology 2004;370(4):279-89.
2004: Jarkko I Venäläinen; Risto O Juvonen; J Arturo Garcia-Horsman; Erik A A Wallén; Johannes A M Christiaans; Elina M Jarho; Jukka Gynther; Pekka T Männistö
Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site.
The Biochemical journal 2004;382(Pt 3):1003-8.
2004: Hani El-Nezami; Nektaria Polychronaki; Yuan Kun Lee; Carolyn Haskard; Risto O Juvonen; Seppo Salminen; Hannu M Mykkänen
Chemical moieties and interactions involved in the binding of zearalenone to the surface of Lactobacillus rhamnosus strains GG.
Journal of agricultural and food chemistry 2004;52(14):4577-81.
2004: Jarkko I Venäläinen; Risto O Juvonen; Pekka T Männistö
Evolutionary relationships of the prolyl oligopeptidase family enzymes.
European journal of biochemistry / FEBS 2004;271(13):2705-15.
2004: Antti Mäntylä; Jarkko Rautio; Tapio Nevalainen; Jouko Vepsälainen; Risto O Juvonen; Howard Kendrick; Tracy Garnier; Simon L Croft; Tomi Järvinen
Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives.
Bioorganic & medicinal chemistry 2004;12(13):3497-502.
2003: Arja Asikainen; Juhani Tarhanen; Antti Poso; Markku Pasanen; Esko Alhava; Risto O Juvonen
Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes.
Toxicology in vitro : an international journal published in association with BIBRA 2003;17(4):449-55.
2003: Minna Rahnasto; Hannu Raunio; Antti Poso; Risto O Juvonen
More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde.
Xenobiotica; the fate of foreign compounds in biological systems 2003;33(5):529-39.
2002: Cecilia Odlind; Ilkka Reenilä; Pekka T Männistö; Risto O Juvonen; Staffan Uhlén; Joseph A Gogos; Maria Karayiorgou; Peter Hansell
Reduced natriuretic response to acute sodium loading in COMT gene deleted mice.
BMC physiology 2002;2():14.
2002: Jarkko I Venäläinen; Risto O Juvonen; Markus M Forsberg; Arturo Garcia-Horsman; Antti Poso; Erik A A Wallen; Jukka Gynther; Pekka T Männistö
Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819.
Biochemical pharmacology 2002;64(3):463-71.
2002: Raimo Pohjanvirta; Merja Korkalainen; J McGuire; Ulla Simanainen; Risto O Juvonen; Jouni T Tuomisto; M Unkila; Matti Viluksela; J Bergman; L Poellinger; Jouko Tuomisto
Comparison of acute toxicities of indolo[3,2-b]carbazole (ICZ) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in TCDD-sensitive rats.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2002;40(7):1023-32.
2001: Antti Poso; Jukka Gynther; Risto O Juvonen
A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors.
Journal of computer-aided molecular design 2001;15(3):195-202.
2001: Päivi Taavitsainen; Risto O Juvonen; Olavi Pelkonen
In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(3):217-22.
2000: Onni Niemelä; Seppo Parkkila; Risto O Juvonen; Katja Viitala; H V Gelboin; Markku Pasanen
Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases.
Journal of hepatology 2000;33(6):893-901.
2000: P Pellinen; L Kulmala; J Konttila; S Auriola; Markku Pasanen; Risto O Juvonen
Kinetic characteristics of norcocaine N-hydroxylation in mouse and human liver microsomes: involvement of CYP enzymes.
Archives of toxicology 2000;74(9):511-20.
2000: Risto O Juvonen; Jukka Gynther; M Pasanen; E Alhava; Antti Poso
Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases (CYP2A5 and CYP2A6).
Xenobiotica; the fate of foreign compounds in biological systems 2000;30(1):81-92.
1998: A Kojo; Pirkko Viitala; Markku Pasanen; Olavi Pelkonen; Hannu Raunio; Risto O Juvonen
Induction of CYP2A5 by pyrazole and its derivatives in mouse primary hepatocytes.
Archives of toxicology 1998;72(6):336-41.
1998: Hannu Raunio; Risto O Juvonen; Markku Pasanen; Olavi Pelkonen; P Pääkkö; Y Soini
Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma.
Hepatology (Baltimore, Md.) 1998;27(2):427-32.
1997: P Pelkonen; M A Lang; M Negishi; Christopher P Wild; Risto O Juvonen
Interaction of aflatoxin B1 with cytochrome P450 2A5 and its mutants: correlation with metabolic activation and toxicity.
Chemical research in toxicology 1997;10(1):85-90.
1996: A Kojo; P Pellinen; Risto O Juvonen; Hannu Raunio; Olavi Pelkonen; Markku Pasanen
Distinct responses of mouse hepatic CYP enzymes to corn oil and peroxisome proliferators.
Biochemical pharmacology 1996;51(9):1137-43.
1996: Sirpa Pennanen; A Kojo; M Pasanen; Jyrki Liesivuori; Risto O Juvonen; Hannu Komulainen
CYP enzymes catalyze the formation of a terminal olefin from 2-ethylhexanoic acid in rat and human liver.
Human & experimental toxicology 1996;15(5):435-42.
1995: T Kinonen; Markku Pasanen; Jukka Gynther; A Poso; Tomi Järvinen; E Alhava; Risto O Juvonen
Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6.
British journal of pharmacology 1995;116(6):2625-30.
1995: Jarmo T Laitinen; Risto O Juvonen
A sensitive microassay reveals marked regional differences in the capacity of rat brain to generate carbon monoxide.
Brain research 1995;694(1-2):246-52.
1995: T Kimonen; Risto O Juvonen; E Alhava; Markku Pasanen
The inhibition of CYP enzymes in mouse and human liver by pilocarpine.
British journal of pharmacology 1995;114(4):832-6.
1995: Markku Pasanen; P Pellinen; Frej Stenbäck; Risto O Juvonen; Hannu Raunio; Olavi Pelkonen
The role of CYP enzymes in cocaine-induced liver damage.
Archives of toxicology 1995;69(5):287-90.
1994: P Pelkonen; M A Lang; Christopher P Wild; M Negishi; Risto O Juvonen
Activation of aflatoxin B1 by mouse CYP2A enzymes and cytotoxicity in recombinant yeast cells.
European journal of pharmacology 1994;292(1):67-73.
1994: J Mäenpää; Risto O Juvonen; Hannu Raunio; Arja Rautio; Olavi Pelkonen
Metabolic interactions of methoxsalen and coumarin in humans and mice.
Biochemical pharmacology 1994;48(7):1363-9.
1993: Paavo Honkakoski; J Mäenpää; J Leikola; Markku Pasanen; Risto O Juvonen; M A Lang; Olavi Pelkonen; Hannu Raunio
Cytochrome P4502A-mediated coumarin 7-hydroxylation and testosterone hydroxylation in mouse and rat lung.
Pharmacology & toxicology 1993;72(2):107-12.
1992: B Hahnemann; P Salonpää; Markku Pasanen; J Mäenpää; Paavo Honkakoski; Risto O Juvonen; M A Lang; Olavi Pelkonen; Hannu Raunio
Effect of pyrazole, cobalt and phenobarbital on mouse liver cytochrome P-450 2a-4/5 (Cyp2a-4/5) expression.
The Biochemical journal 1992;286 ( Pt 1)():289-94.
1992: Paavo Honkakoski; P Arvela; Risto O Juvonen; M A Lang; M Kairaluoma; Olavi Pelkonen
Human and mouse liver coumarin 7-hydroxylases do not metabolize warfarin in vitro.
British journal of clinical pharmacology 1992;33(3):313-7.
1991: A Kojo; R Heiskanen; A L Rytkönen; Paavo Honkakoski; Risto O Juvonen; M Lang
Inducibility of P450Coh by pyrazole and its derivatives.
Biochemical pharmacology 1991;42(9):1751-9.
1990: Raimo Pohjanvirta; H Håkansson; Risto O Juvonen; J Tuomisto
Effects of TCDD on vitamin A status and liver microsomal enzyme activities in a TCDD-susceptible and a TCDD-resistant rat strain.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 1990;28(3):197-203.
1989: M A Lang; Risto O Juvonen; P Järvinen; Paavo Honkakoski; Hannu Raunio
Mouse liver P450Coh: genetic regulation of the pyrazole-inducible enzyme and comparison with other P450 isoenzymes.
Archives of biochemistry and biophysics 1989;271(1):139-48.
1989: Raimo Pohjanvirta; T Kulju; A F Morselt; R Tuominen; Risto O Juvonen; K Rozman; P Männistö; Y Collan; E L Sainio; J Tuomisto
Target tissue morphology and serum biochemistry following 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure in a TCDD-susceptible and a TCDD-resistant rat strain.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1989;12(4):698-712.
1988: Paavo Honkakoski; S Autio; Risto O Juvonen; Hannu Raunio; H V Gelboin; S S Park; Olavi Pelkonen; M A Lang
Pyrazole is different from acetone and ethanol as an inducer of the polysubstrate monooxygenase system in mice: evidence that pyrazole-inducible P450Coh is distinct from acetone-inducible P450ac.
Archives of biochemistry and biophysics 1988;267(2):589-98.
1988: Paavo Honkakoski; A Kojo; Hannu Raunio; Markku Pasanen; Risto O Juvonen; M A Lang
Hepatic mitochondrial coumarin 7-hydroxylase: comparison with the microsomal enzyme.
Archives of biochemistry and biophysics 1988;267(2):558-67.
1988: Hannu Raunio; A Kojo; Risto O Juvonen; Paavo Honkakoski; P Järvinen; M A Lang; Kirsi Vähäkangas; H V Gelboin; S S Park; Olavi Pelkonen
Mouse hepatic cytochrome P-450 isozyme induction by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene, pyrazole, and phenobarbital.
Biochemical pharmacology 1988;37(21):4141-7.
1988: Hannu Raunio; T Syngelmä; Markku Pasanen; Risto O Juvonen; Paavo Honkakoski; M A Kairaluoma; E Sotaniemi; M A Lang; Olavi Pelkonen
Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse.
Biochemical pharmacology 1988;37(20):3889-95.
1988: Risto O Juvonen; V M Shkumatov; M A Lang
Purification and characterization of a liver microsomal cytochrome P-450 isoenzyme with a high affinity and metabolic capacity for coumarin from pyrazole-treated D2 mice.
European journal of biochemistry / FEBS 1988;171(1-2):205-11.
1988: Raimo Pohjanvirta; Risto O Juvonen; S Kärenlampi; Hannu Raunio; J Tuomisto
Hepatic Ah-receptor levels and the effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on hepatic microsomal monooxygenase activities in a TCDD-susceptible and -resistant rat strain.
Toxicology and applied pharmacology 1988;92(1):131-40.
1987: Risto O Juvonen; S Autio; M A Lang
Pyrazole as a modifier of liver microsomal monooxygenase in DBA/2N and AKR/J mice.
Biochemical pharmacology 1987;36(22):3993-7.
1985: Risto O Juvonen; P K Kaipainen; M A Lang
Selective induction of coumarin 7-hydroxylase by pyrazole in D2 mice.
European journal of biochemistry / FEBS 1985;152(1):3-8.